NCT07099547View on ClinicalTrials.gov

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Biliary Tract Carcinoma
Interventions
DRUG

ZG005

ZG005 20 mg/kg IV Q3W

DRUG

Tislelizumab

Tislelizumab 200mg IV Q3W

DRUG

Gemcitabine

Gemcitabine 1000mg/m\^2 Q3W. Gemcitabine will be administered on D1/D8 in every three weeks cycle.

DRUG

Cisplatin

Cisplatin 25mg/m\^2 Q3W. Cisplatin will be administered on D1/D8 in every three weeks cycle.

Trial Locations (1)

230001

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY